These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8314932)

  • 21. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
    Choi HJ; Lee SY; Cho Y; Hwang O
    Neurochem Int; 2005 Mar; 46(4):329-35. PubMed ID: 15707697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum.
    Nissbrandt H; Sundström E; Jonsson G; Hjorth S; Carlsson A
    J Neurochem; 1989 Apr; 52(4):1170-82. PubMed ID: 2564423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of cyanide with a dopamine metabolite: formation of a cyanohydrin adduct and its implications for cyanide-induced neurotoxicity.
    Kanthasamy AG; Rathinavelu A; Borowitz JL; Isom GE
    Neurotoxicology; 1994; 15(4):887-95. PubMed ID: 7715859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemistry of neuromelanin.
    Van Woert MH; Ambani LM
    Adv Neurol; 1974; 5():215-23. PubMed ID: 4374063
    [No Abstract]   [Full Text] [Related]  

  • 25. Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein.
    Werner-Allen JW; DuMond JF; Levine RL; Bax A
    Angew Chem Int Ed Engl; 2016 Jun; 55(26):7374-8. PubMed ID: 27158766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra.
    Elverfors A; Pileblad E; Lagerkvist S; Bergquist F; Jonason J; Nissbrandt H
    J Neurochem; 1997 Oct; 69(4):1684-92. PubMed ID: 9326297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
    Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
    J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.
    Yu PH; Bailey BA; Durden DA; Boulton AA
    Biochem Pharmacol; 1986 Mar; 35(6):1027-36. PubMed ID: 3954792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease.
    Mattammal MB; Strong R; Lakshmi VM; Chung HD; Stephenson AH
    J Neurochem; 1995 Apr; 64(4):1645-54. PubMed ID: 7891092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
    Gerhardt GA; Cass WA; Huettl P; Brock S; Zhang Z; Gash DM
    Brain Res; 1999 Jan; 817(1-2):163-71. PubMed ID: 9889359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous determination of the rates of synthesis and metabolism of dopamine in various areas of the rat brain: application to the effects of (+)-amphetamine.
    Westerink BH; Van Putten FM
    Eur J Pharmacol; 1987 Jan; 133(1):103-10. PubMed ID: 3104064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
    Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
    Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural toxin implicated as triggering Parkinson's disease.
    Pak J Biol Sci; 2011 Feb; 14(3):255. PubMed ID: 21870660
    [No Abstract]   [Full Text] [Related]  

  • 35. Catabolism of endogenous dopamine in peripheral tissues: is there an independent role for dopamine in peripheral neurotransmission?
    Lacković Z; Relja M; Neff NH
    J Neurochem; 1982 May; 38(5):1453-8. PubMed ID: 7062061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.
    Uemura MT; Asano T; Hikawa R; Yamakado H; Takahashi R
    Neurosci Res; 2017 Nov; 124():25-32. PubMed ID: 28624436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromelanin of the human substantia nigra: a mixed-type melanin.
    Odh G; Carstam R; Paulson J; Wittbjer A; Rosengren E; Rorsman H
    J Neurochem; 1994 May; 62(5):2030-6. PubMed ID: 8158151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proceedings: Lack of significance of MAO-B for in vivo deamination of dopamine.
    Waldmeier PC; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R2. PubMed ID: 1143400
    [No Abstract]   [Full Text] [Related]  

  • 40. 1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol depletes catecholamines in rat brain.
    Liptrot J; Holdup D; Phillipson O
    J Neurochem; 1993 Dec; 61(6):2199-206. PubMed ID: 7504086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.